GSK Reportedly To Lay Off 1,000 In China
This article was originally published in PharmAsia News
After a stormy year in China, GSK has gone through major changes including the global transfer of its oncology assets to Novartis. But the underlying broader reasons for the company’s newly reported layoffs in China could be more deep-rooted and far-reaching.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
With gene editing making the news again after the recent Nobel Prize for CRISPR, China’s EdiGene has been raising new funds to accelerate its pipeline to the clinic, led by a potential one-time cure for thalassemia and helped by recent regulatory changes.